UNCY · Unicycive Therapeutics Inc. Common Stock
View on chartInsiders & Stakes
| Gupta Shalabh K. CEO | ▲ Buy | Option Exercise | 2,527,449 Shares held | 7/11/2023 | View profile |
| Aggarwal Gaurav Director | ▼ Sell | Other | 1,789,915 Shares held | 8/25/2025 | View profile |
| Jermasek Douglas EVP of Corporate Strategy | ▲ Buy | Option Exercise | 175,012 Shares held | 7/11/2023 | View profile |
| Gupta Pramod EVP, Pharmaceuticals and BD | ▲ Buy | Option Exercise | 41,845 Shares held | 7/11/2023 | View profile |
| Schiller Brigitte Director | ▲ Buy | Option Exercise | 26,738 Shares held | 7/15/2022 | View profile |
Transaction History
| Aggarwal Gaurav | ▼ Sell | Other | 652,900 | — | 8/25/2025 |
| Aggarwal Gaurav | ▼ Sell | Other | 1,400,000 | — | 2/18/2025 |
| Aggarwal Gaurav | ▼ Sell | Other | 5,500,000 | — | 10/9/2024 |
| Jermasek Douglas | ▲ Buy | Option Exercise | 104,612 | — | 7/11/2023 |
| Gupta Pramod | ▲ Buy | Option Exercise | 41,845 | — | 7/11/2023 |
| Gupta Shalabh K. | ▲ Buy | Option Exercise | 104,612 | — | 7/11/2023 |
| Aggarwal Gaurav | ▼ Sell | Other | 3,470,152 | — | 7/11/2023 |
| Schiller Brigitte | ▲ Buy | Option Exercise | 26,738 | $0 | 7/15/2022 |
| Schiller Brigitte | ▲ Buy | Open Market | 15,000 | $12K | 5/16/2022 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
Unicycive Resubmits FDA Application Amid Securities Lawsuit
Unicycive Therapeutics has resubmitted its FDA application for oxylanthanum carbonate, targeting a PDUFA date six months from now. This regulatory update comes alongside a securities class action filed in September, alleging violations related to previous statements about the drug application. The stock is currently trading near its 52-week low, reflecting the combined weight of legal and regulatory developments.
Unicycive Resubmits FDA Application Amid Securities Lawsuit. Unicycive Therapeutics has resubmitted its FDA application for oxylanthanum carbonate, targeting a PDUFA date six months from now. This regulatory update comes alongside a securities class action filed in September, alleging violations related to previous statements about the drug application. The stock is currently trading near its 52-week low, reflecting the combined weight of legal and regulatory developments.